Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

First database of combined clinical trials on brain disease made available to qualified researchers

A new database of more than 4,000 Alzheimer's disease patients who have participated in 11 industry-sponsored clinical trials was released today by the Coalition Against Major Diseases. This is the first database of combined clinical trials to be openly shared by pharmaceutical companies and made available to qualified researchers around the world.

14 Jun 2010

Amorfix Life Sciences reports operational and year-end financial results for fiscal 2010

Amorfix Life Sciences, a company focused on the development of therapeutic monoclonal antibodies and diagnostics for the treatment of fatal neurodegenerative diseases and cancer, today announced its operational and financial results for the year ended March 31, 2010, as well as financial results for the fourth quarter.

11 Jun 2010

In vivo structure of senile plaques in brains of people with Alzheimer's disease

A team of scientists from Britain and the United States believe they may have identified the true in vivo structure of the senile plaques that are characteristically found in the brains of people with Alzheimer's disease.

11 Jun 2010

CinGx safe and effective for treating diabetes, Alzheimer’s and dementia

There is currently no cure for Diabetes, Alzheimer's and Dementia but they can be treated and prevented. Allegiance Equity developed CinGx™ as a safe and effective treatment for these diseases.

11 Jun 2010

New computer program allows early diagnosis of Alzheimer's disease

Researchers of the University of Granada have developed a new computer program that allows early diagnosis of Alzheimer's disease through processed images.

11 Jun 2010

DZNE, MRC and CIHR sign cooperation agreement for research on neurodegenerative diseases

Representatives of the German Centre for Neurodegenerative Diseases, the UK Medical Research Council and the Canadian Institutes of Health Research today signed a cooperation agreement that aims to establish and apply harmonised guidelines and technologies for research on neurodegenerative diseases.

11 Jun 2010

Ginkgo extract EGb 761 promotes formation of new nerve cells, cell connections in brain's memory center

US scientists have shown that the Ginkgo extract EGb 761® promotes the formation of new nerve cells and new cell connections in the hippocampus, the brain's memory center. According to Professor Yuan Luo from the University of Maryland, Baltimore, the Ginkgo constituents responsible for these effects are quercetin and bilobalide.

11 Jun 2010

Researchers develop new computer program for early diagnosis of Alzheimer's disease

Researchers of the University of Granada have developed a new computer program that allows early diagnosis of Alzheimer's disease through processed images. This new system has enhanced successful early diagnosis of Alzheimer's disease up to 90%, which is an important progress within this area of study.

10 Jun 2010

HDMA honors Upsher-Smith with two DIANA Awards

Upsher-Smith announced today that they are the recipients of two Distribution Industry Awards for Notable Achievements in Healthcare given by the Healthcare Distribution Management Association. The Company was presented with two DIANAs in the 'Best Overall Manufacturer' Awards category. Within this category, Upsher-Smith was the winner for the second time since 2008 of the 'Best Branded Pharmaceutical Company with Sales to Healthcare Distributors of less than $300 Million.'

10 Jun 2010

Brain stimulation with ultrasound may enhance cognitive function

The ability to diagnose and treat brain dysfunction without surgery, may rely on a new method of noninvasive brain stimulation using pulsed ultrasound developed by a team of scientists led by William "Jamie" Tyler, a neuroscientist at Arizona State University. The approach, published in the journal Neuron on June 9, shows that pulsed ultrasound not only stimulates action potentials in intact motor cortex in mice but it also "elicits motor responses comparable to those only previously achieved with implanted electrodes and related techniques," says Yusuf Tufail, the lead author from ASU's School of Life Sciences.

10 Jun 2010

Caregiver's guide on avoiding life-threatening swallowing problems

That's the message of Drs. Roya Sayadi and Joel Herskowitz. They are a wife-husband team from Natick, Massachusetts, who are spreading the word that swallowing problems are everywhere - and they can be deadly!

10 Jun 2010

Study: ChEI improves driving skills in patients with mild AD

A promising study from Rhode Island Hospital demonstrated that cholinesterase inhibitors, a type of medication often prescribed for Alzheimer's disease, improved some cognitive skills in patients with mild AD - skills that are necessary for driving. Findings from the study showed that after being treated with a ChEI, AD patients improved in some computerized tests of executive function and visual attention, including a simulated driving task.

10 Jun 2010

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

CoLucid Pharmaceuticals, Inc.,, an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study.

10 Jun 2010

Abnormalities in the process of blood clot formation contribute to pathogenesis of AD: Research

New research suggests that abnormalities in the process of blood clot formation may contribute to the pathogenesis of Alzheimer's disease. The study, published by Cell Press in the June 10 issue of the journal Neuron, advances our understanding of the link between vascular pathology and AD and proposes a new therapeutic strategy aimed at slowing cognitive decline.

10 Jun 2010

Intellect Neurosciences receives Notice of Allowance from Israeli patent office for OXIGON drug candidate

Intellect Neurosciences, Inc announced it has received a Notice of Allowance from the Israeli Patent and Trademark Office for a new patent related to the Company's clinical-stage drug candidate OX1 (OXIGON), which has disease-modifying potential for Alzheimer's and other neurodegenerative disorders.

9 Jun 2010

Scientists develop algorithm to predict gene sequence of kinases

Kinexus Bioinformatics Corporation, a world-leader in molecular communications research, announced major advancements in its PhosphoNET KnowledgeBase for the study of cell signalling systems. This free resource to the scientific community now features data on more than 92,000 human phosphorylation sites, including their occurrence in over 20 other diverse species, and identification of the protein kinases that target these regulatory sites.

9 Jun 2010

Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol

Resverlogix is pleased to announce that it has collaborated with the Division of Cardiology at the Research Institute of the McGill University Health Centre (RI of the MUHC), to publish today in the Journal of American College of Cardiology (JACC), a report entitled 'RVX-208 A Small Molecule that Increases Apolipoprotein A-I and High Density Lipoprotein Cholesterol In Vitro and In Vivo'.

9 Jun 2010

Pecans may delay progression of age-related motor neuron degeneration: Study

Eating about a handful of pecans each day may play a role in protecting the nervous system, according to a new animal study published in the current issue of Current Topics in Nutraceutical Research. The study, conducted at the Center for Cellular Neurobiology at the University of Massachusetts Lowell, suggests adding pecans to your diet may delay the progression of age-related motor neuron degeneration. This may include diseases like amyotropic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.

9 Jun 2010

Pharnext closes €4.8-million Series A funding round

Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments based on Pleotherapy™ for severe neurological diseases, today announced that it had closed a €4.8-million Series A round of funding on June 3rd (corresponding to a company valuation of €45 million).

9 Jun 2010

Switching to healthier diet can slow or reverse cognitive impairment in patients with Alzheimer's Disease: Study

Patients in the early to moderate stages of Alzheimer's Disease could have their cognitive impairment slowed or even reversed by switching to a healthier diet, according to researchers at Temple University.

9 Jun 2010

Alzheimer's Disease News and Research

Further Reading

First database of combined clinical trials on brain disease made available to qualified researchers

Amorfix Life Sciences reports operational and year-end financial results for fiscal 2010

In vivo structure of senile plaques in brains of people with Alzheimer's disease

CinGx safe and effective for treating diabetes, Alzheimer’s and dementia

New computer program allows early diagnosis of Alzheimer's disease

DZNE, MRC and CIHR sign cooperation agreement for research on neurodegenerative diseases

Ginkgo extract EGb 761 promotes formation of new nerve cells, cell connections in brain's memory center

Researchers develop new computer program for early diagnosis of Alzheimer's disease

HDMA honors Upsher-Smith with two DIANA Awards

Brain stimulation with ultrasound may enhance cognitive function

Caregiver's guide on avoiding life-threatening swallowing problems

Study: ChEI improves driving skills in patients with mild AD

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

Abnormalities in the process of blood clot formation contribute to pathogenesis of AD: Research

Intellect Neurosciences receives Notice of Allowance from Israeli patent office for OXIGON drug candidate

Scientists develop algorithm to predict gene sequence of kinases

Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol

Pecans may delay progression of age-related motor neuron degeneration: Study

Pharnext closes €4.8-million Series A funding round

Switching to healthier diet can slow or reverse cognitive impairment in patients with Alzheimer's Disease: Study

Aneuro: A Year of Neuroscience in Review eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News